Anticancer properties of 4-thiazolidinone derivatives depend on peroxisome proliferator-activated receptor gamma (PPARγ)
- 1 December 2017
- journal article
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 141, 162-168
Abstract
No abstract availableKeywords
Funding Information
- University of Information Technology and Management in Rzeszow, Poland (DS 503-07-02-21)
This publication has 33 references indexed in Scilit:
- Fused Thiopyrano[2,3-d]thiazole Derivatives as Potential Anticancer AgentsScientia Pharmaceutica, 2012
- HL005—A new selective PPARγ antagonist specifically inhibits the proliferation of MCF-7The Journal of Steroid Biochemistry and Molecular Biology, 2011
- Thiazolidinone motif in anticancer drug discovery. Experience of DH LNMU medicinal chemistry scientific groupBiopolymers and Cell, 2011
- Energy Restriction as an Antitumor Target of ThiazolidinedionesJournal of Biological Chemistry, 2010
- Mitochondria, PPARs, and Cancer: Is Receptor‐Independent Action of PPAR Agonists a Key?PPAR Research, 2008
- The Role of PPARs in CancerPPAR Research, 2008
- The Many Faces of PPARγCell, 2005
- Antineoplastic effects of peroxisome proliferatoractivated receptor γ agonistsThe Lancet Oncology, 2004
- Resistin is expressed in human macrophages and directly regulated by PPARγ activatorsBiochemical and Biophysical Research Communications, 2003
- Feedback Control of Cyclooxygenase-2 Expression through PPARγJournal of Biological Chemistry, 2000